Cargando…

Clinicians’ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study

(1) Background: Given the high prevalence of non-alcoholic fatty liver disease (NAFLD) and the limitations of liver biopsies, multiple non-invasive tests (NITs) have been developed to identify non-alcoholic fatty liver disease (NAFLD) patients at-risk of progression. The availability of these new NI...

Descripción completa

Detalles Bibliográficos
Autores principales: Vali, Yasaman, Eijk, Roel, Hicks, Timothy, Jones, William S., Suklan, Jana, Holleboom, Adriaan G., Ratziu, Vlad, Langendam, Miranda W., Anstee, Quentin M., Bossuyt, Patrick M. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146541/
https://www.ncbi.nlm.nih.gov/pubmed/35628838
http://dx.doi.org/10.3390/jcm11102707
_version_ 1784716588586369024
author Vali, Yasaman
Eijk, Roel
Hicks, Timothy
Jones, William S.
Suklan, Jana
Holleboom, Adriaan G.
Ratziu, Vlad
Langendam, Miranda W.
Anstee, Quentin M.
Bossuyt, Patrick M. M.
author_facet Vali, Yasaman
Eijk, Roel
Hicks, Timothy
Jones, William S.
Suklan, Jana
Holleboom, Adriaan G.
Ratziu, Vlad
Langendam, Miranda W.
Anstee, Quentin M.
Bossuyt, Patrick M. M.
author_sort Vali, Yasaman
collection PubMed
description (1) Background: Given the high prevalence of non-alcoholic fatty liver disease (NAFLD) and the limitations of liver biopsies, multiple non-invasive tests (NITs) have been developed to identify non-alcoholic fatty liver disease (NAFLD) patients at-risk of progression. The availability of these new NITs varies from country to country, and little is known about their implementation and adoption in routine clinical practice. This study aims to explore barriers and facilitators that influence the adoption of NAFLD NITs, from healthcare professionals’ perspectives. (2) Methods: A cross-sectional study was performed using an exploratory mixed-methods approach. Twenty-seven clinicians from eight different countries with different specialties filled in our questionnaire. Of those, 16 participated in semi-structured interviews. Qualitative and quantitative data were collected and summarized using the recently published Non-adoption, Abandonment, Scale-up, Spread, and Sustainability (NASSS) framework for new medical technologies in healthcare organizations. (3) Results: Several factors were reported as influencing the uptake of NITs for NAFLD in clinical practice. Among those: insufficient awareness of tests; lack of practical guidelines and evidence for the performance of tests in appropriate patient populations and care settings; and absence of sufficient reimbursement systems were reported as the most important barriers. Other factors, most notably ‘local champions’, proper functional payment systems, and sufficient resources in academic hospitals, were indicated as important facilitating factors. (4) Conclusions: Clinicians see the adoption of NITs for NAFLD as a complex process that is modulated by several factors, such as robust evidence, practical guidelines, a proper payment system, and local champions. Future research could explore perspectives from other stakeholders on the adoption of NITs.
format Online
Article
Text
id pubmed-9146541
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91465412022-05-29 Clinicians’ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study Vali, Yasaman Eijk, Roel Hicks, Timothy Jones, William S. Suklan, Jana Holleboom, Adriaan G. Ratziu, Vlad Langendam, Miranda W. Anstee, Quentin M. Bossuyt, Patrick M. M. J Clin Med Article (1) Background: Given the high prevalence of non-alcoholic fatty liver disease (NAFLD) and the limitations of liver biopsies, multiple non-invasive tests (NITs) have been developed to identify non-alcoholic fatty liver disease (NAFLD) patients at-risk of progression. The availability of these new NITs varies from country to country, and little is known about their implementation and adoption in routine clinical practice. This study aims to explore barriers and facilitators that influence the adoption of NAFLD NITs, from healthcare professionals’ perspectives. (2) Methods: A cross-sectional study was performed using an exploratory mixed-methods approach. Twenty-seven clinicians from eight different countries with different specialties filled in our questionnaire. Of those, 16 participated in semi-structured interviews. Qualitative and quantitative data were collected and summarized using the recently published Non-adoption, Abandonment, Scale-up, Spread, and Sustainability (NASSS) framework for new medical technologies in healthcare organizations. (3) Results: Several factors were reported as influencing the uptake of NITs for NAFLD in clinical practice. Among those: insufficient awareness of tests; lack of practical guidelines and evidence for the performance of tests in appropriate patient populations and care settings; and absence of sufficient reimbursement systems were reported as the most important barriers. Other factors, most notably ‘local champions’, proper functional payment systems, and sufficient resources in academic hospitals, were indicated as important facilitating factors. (4) Conclusions: Clinicians see the adoption of NITs for NAFLD as a complex process that is modulated by several factors, such as robust evidence, practical guidelines, a proper payment system, and local champions. Future research could explore perspectives from other stakeholders on the adoption of NITs. MDPI 2022-05-11 /pmc/articles/PMC9146541/ /pubmed/35628838 http://dx.doi.org/10.3390/jcm11102707 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Vali, Yasaman
Eijk, Roel
Hicks, Timothy
Jones, William S.
Suklan, Jana
Holleboom, Adriaan G.
Ratziu, Vlad
Langendam, Miranda W.
Anstee, Quentin M.
Bossuyt, Patrick M. M.
Clinicians’ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study
title Clinicians’ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study
title_full Clinicians’ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study
title_fullStr Clinicians’ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study
title_full_unstemmed Clinicians’ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study
title_short Clinicians’ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study
title_sort clinicians’ perspectives on barriers and facilitators for the adoption of non-invasive liver tests for nafld: a mixed-method study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146541/
https://www.ncbi.nlm.nih.gov/pubmed/35628838
http://dx.doi.org/10.3390/jcm11102707
work_keys_str_mv AT valiyasaman cliniciansperspectivesonbarriersandfacilitatorsfortheadoptionofnoninvasivelivertestsfornafldamixedmethodstudy
AT eijkroel cliniciansperspectivesonbarriersandfacilitatorsfortheadoptionofnoninvasivelivertestsfornafldamixedmethodstudy
AT hickstimothy cliniciansperspectivesonbarriersandfacilitatorsfortheadoptionofnoninvasivelivertestsfornafldamixedmethodstudy
AT joneswilliams cliniciansperspectivesonbarriersandfacilitatorsfortheadoptionofnoninvasivelivertestsfornafldamixedmethodstudy
AT suklanjana cliniciansperspectivesonbarriersandfacilitatorsfortheadoptionofnoninvasivelivertestsfornafldamixedmethodstudy
AT holleboomadriaang cliniciansperspectivesonbarriersandfacilitatorsfortheadoptionofnoninvasivelivertestsfornafldamixedmethodstudy
AT ratziuvlad cliniciansperspectivesonbarriersandfacilitatorsfortheadoptionofnoninvasivelivertestsfornafldamixedmethodstudy
AT langendammirandaw cliniciansperspectivesonbarriersandfacilitatorsfortheadoptionofnoninvasivelivertestsfornafldamixedmethodstudy
AT ansteequentinm cliniciansperspectivesonbarriersandfacilitatorsfortheadoptionofnoninvasivelivertestsfornafldamixedmethodstudy
AT bossuytpatrickmm cliniciansperspectivesonbarriersandfacilitatorsfortheadoptionofnoninvasivelivertestsfornafldamixedmethodstudy